



Our STN: BL 103772/5058

JUL 29 2004

Centocor, Incorporated
Attention: Stella Jones, Ph.D.
Vice President, Worldwide Regulatory Affairs
200 Great Valley Parkway
Malvern, PA 19355-1307

Dear Dr. Jones:

Your request to supplement your biologics license application for Infliximab to revise the Warnings section of the package insert to include leukopenia, neutropenia, thrombocytopenia, and CNS manifestations of systemic vasculitis, and to revise the Adverse Reactions section to include neutropenia, pericardial effusion and systemic and cutaneous vasculitis, and to update the patient information sheet has been approved.

We acknowledge your written commitment of May 11, 2004, to provide a draft Dear Healthcare Provider Letter to FDA for review. The draft Dear Healthcare Professional Letter should inform physicians and other healthcare providers of the updated information in the Warnings and the Adverse Reactions sections of the package insert, and the patient information sheet. As provided in your facsimile of July 26, 2004, the Dear Healthcare Professional Letter will be submitted by August 27, 2004.

Pursuant to 21 CFR 201.57(f)(2), patient labeling must be reprinted at the end of the package insert. We request that the text of information distributed to patients be printed in a minimum of 10 point font.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

The regulatory responsibility for review and continuing oversight for this product transferred from the Center for Biologics Evaluation and Research to the Center for Drug Evaluation and Research effective June 30, 2003. For further information about the transfer, please see <http://www.fda.gov/cber/transfer/transfer.htm> and <http://www.fda.gov/OHRMS/DOCKETS/98fr/03-16242.html>. Until further notice, however, all correspondence, except as provided elsewhere in this letter, should continue to be addressed to:

CBER Document Control Center
Attn: Office of Therapeutics Research and Review
Suite 200N (HFM-99)
1401 Rockville Pike
Rockville, Maryland 20852-1448

This information will be included in your biologics license application file.

Sincerely,

(b)(6)

Marc Walton, M.D., Ph.D.
Director
Division of Therapeutic Biological Internal Medicine Products
Office of Drug Evaluation VI
Center for Drug Evaluation and Research

CONCURRENCE PAGE

Letter Type: LETTER: Approval (AP)
Summary Text: Clinical Supplmt. – Labeling Only
REVIEW COMPLETION REQUIRED BY: RIS

SS Data Check:

- Place copy of Approval Ltr. with original signature concurrence page in Archival package behind the “Approval Materials” Tab after LAR (Licensing Action Recommendation).

RIS Data Check:

- Verify short summary – Ltr. & Submission screen should match.
- Check Letter for PMCs (if PMCs – add “PMCs – Approved With” special characteristic code.)
- Perform Review Completion Process
- Milestone: Confirm Approved Status

cc: S. Kozlowski, HFM-561
P. Swann, HFM-555
M. Walton, HFM-570
DARP BLA file, HFM-585
K. Weiss, HFM-500
QAS, HFM-4
RIMS, HFM-110
B. Conner, HFM-588
J. Siegel, HFM- 582
K. Hull, HFM-582
E. Unger, HFM-582
C. O’Leary, HFM-588
Eva Barrion, DDMAC, HFD-42 (with final draft PI)
E. Rivera-Martinez, IPCB, HFD-322
OCTMA, HFM-40 (with final draft PI)
HFD-013/D. Taub , (ORP/DIDP w/revised labeling)
HFD-013/H. Brubaker, (ORP/DIDP w/revised labeling)
Mary Dempsey, OPSS, HFD-400
H. Brubaker, ORP/DIDP, HFD-013
T. Martin, OEP, HFD-006

History: B. Conner: 11/12/03:5.13.04:K. Townsend: 11.13.2003:11/14/03: Hurley:
11.14.2003:K. Townsend: 11.26.2003: 5.14.2004: T. Pagan-Motta: 7.1.04: T. Pagan-Motta:
7.6.04: T. Pagan-Motta: 7.26.04: T. Pagan-Motta: 7.27.04

File Name: S:Conner\BLA\Letters\103772_5058AP

(b)(6)

